VENORUTON (Capsules)

Active material: Rutozid
When ATH: C05CA01
CCF: The drug with venous and angioprotective action
ICD-10 codes (testimony): H35.0, H36.0, I83, I83.2, I84, I87.0, I87.2, T14.0, T14.3
When CSF: 01.15.01.01
Manufacturer: NOVARTIS CONSUMER HEALTH S.A. (Switzerland)

Pharmaceutical form, composition and packaging

◊ Capsules gelatin, matt, yellow-beige, without smell, with an inscription “Venoluton 300”; contents of capsules – Powder from yellow to brownish-yellow, without smell.

Excipients: polyethylene glycol 6000, gelatin, Titanium dioxide, iron dioxide.

10 PC. – blisters (2) – cardboard boxes.
10 PC. – blisters (5) – cardboard boxes.

◊ Effervescent tablets round, Valium, yellow color, chamfered, with orange scent; rough surface with splashes.

Excipients: Citric acid anhydrous, potassium carbonate, Kalia hydrocarbon, natriya carbonate, macrogol 6000, acesulfame potassium, Povidone K29-32, orange flavor 77909-71, magnesium stearate.

15 PC. – Packaging Polypropylene (1) control system of the first opening – cardboard boxes.

Pharmacological action

The drug has angioprotective and flebotoniziruyuschee action. A derivative of rutin. It operates mainly in the capillaries and veins.

It reduces pores between the endothelial cells by modifying the fiber matrix, located between endothelial cells. It inhibits aggregation and increases the deformability of red blood cells. Anti-inflammatory effect.

In chronic venous insufficiency Venoruton^® It reduces the severity of her symptoms as swelling, pain, convulsions, trophic disorders, varicose dermatitis and varicose ulcers. It reduces symptoms, associated with hemorrhoids, incl. pain, exudation, itching and bleeding.

By providing a beneficial effect on permeability and resistance of the capillary walls, the drug helps slow down the development of diabetic retinopathy. Through the influence of Rutoside on the rheological properties of blood, drug helps prevent retinal mikrotrombozov.

Pharmacokinetics

Absorption and distribution

After oral absorption is about 10-15%. C_max plasma levels reached within 1-9 no. During 120 h concentrations are determined; their decline is biexponential manner.

Deduction

T_1/2 is 10-25 no. O-(b-гидроксиэтил)-Rutoside and glucuronic metabolites are excreted mainly in the bile, 3-6% excreted by the kidneys for 48 no.

Testimony

- Chronic venous insufficiency;

- Postflebitichesky syndrome;

- Trophic disorders with varicose veins;

- Varicose ulcer;

- As an adjunct treatment for lymphostasis after sclerotherapy and removing varicose veins;

- Hemorrhoids (pain, exudation, itching and bleeding);

- Venous insufficiency and hemorrhoids during pregnancy, starting with the II trimester;

- As an adjunct treatment of retinopathy in patients with diabetes mellitus, with hypertension and atherosclerosis.

Dosage regimen

Inside a capsule form prescribed in the early treatment 300 mg (1 capsule) 3 times / day with meals. The reduction of symptoms is usually marked for 2 weeks of treatment. It is recommended to continue taking the drug at the same dose or reduce to the minimum maintenance dose 600 mg / day, or suspend treatment. This made the effect persists for 4 weeks.

The capsules are swallowed whole, drinking plenty of water.

The drug is in the form of effervescent tablets appoint 1 g (1 tab. effervescent) 1 time / day. The effect usually develops within 2 weeks, thereafter the treatment is continued at the same dose, or suspend (wherein the achieved effect is retained for at least 4 weeks).

At limfostaze The recommended dose is 3 g / day (by 1 tab. effervescent 3 times / day).

At diabetic retinopathy administered in the form of capsules 0.9-1.8 g / day or tab. Effervescent by 1-2 g / day (in 1-2 admission).

Side effect

From the digestive system: nausea, diarrhea, heartburn.

Allergic reactions: skin rash.

Other: headache, flushing.

Side effects rapidly disappear after cessation of the drug.

Contraindications

- Hypersensitivity to Rutoside or other ingredients;

- I trimester of pregnancy.

Pregnancy and lactation

In clinical trials examined the use Venoruton^® Pregnancy, However, its use in the I trimester not been specifically studied.

Studies, studies in animals, There were no teratogenic and other undesirable effects of the drug on the fetus.

Appoint Venoruton^® inside it is recommended, Only starting from the II trimester of pregnancy, the expected benefit to the mother of his application exceeds the potential risk to the fetus.

Cautions

If use of the drug symptoms of the disease is not reduced, it is recommended to verify the diagnosis.

Overdose

No cases of overdose, which would be accompanied by clinical symptoms, not reported.

Drug Interactions

Action Venoruton^® enhanced by the simultaneous use of ascorbic acid.

Conditions of supply of pharmacies

The drug is resolved to application as an agent Valium holidays.

Conditions and terms

List B. The drug should be stored in a dry, inaccessible to children at temperature not exceeding 30 ° C. Shelf life – 5 years.